Oscar Health Reports Q3 2026 Results, Raises Full-Year Operating Earnings Outlook
Oscar Health reported Q3 2026 revenue of $5.14B, net income of $167.3M, and adjusted EBITDA of $206.9M. The company raised its full-year operating earnings outlook to $850M–$950M and revenue outlook to $19.0B–$19.3B. Membership grew to 2.69M, and the medical loss ratio improved to 84.0%.
How this was made
The 30-second read
Why it matters
The earnings surprise and guidance lift suggest a bullish short‑term outlook for OSCR.
Market read
First‑report earnings with profit and guidance raise make this a high‑value trading signal.
What to watch
Potential regulatory changes to risk‑adjustment methodology could affect future profitability.
Background
Oscar Health filed an 8‑K on Nov 5, 2026 reporting its Q3 results and raising full‑year earnings guidance.
Ticker impact
Oscar Health posted Q3 2026 revenue of $5.14B, net income of $167.3M and raised FY earnings guidance to $850M‑$950M.
likely upward pressure as the market prices in the earnings beat and higher outlook
First‑report earnings release with material profit and a sizable guidance increase for a mid‑cap health insurer.
Market effects
May lift other health‑insurer stocks as the sector shows profitability potential.
U.S. market sentiment could improve in the health‑tech segment.
Limited to U.S. insurers; no broader global effect.
Counterpoint
If the earnings beat is already priced in, the stock could face short‑term profit‑taking.
Key entities
- companyOscar Health
U.S. health‑insurance provider (NASDAQ: OSCR).
